LCL204

LCL204 is a lysosomotropic small molecule inhibitor of acid ceramidase (AC), an enzyme that degrades the pro-apoptotic sphingolipid ceramide into sphingosine and fatty acids. By inhibiting acid ceramidase, LCL204 promotes the accumulation of ceramide within lysosomes, which triggers cell death pathways including apoptosis and autophagy. This compound has been primarily investigated as a potential therapeutic for acute myelogenous leukemia (AML), where it has demonstrated the ability to reduce cell viability and inhibit tumor growth in preclinical models. It is often studied in combination with other sphingolipid-modulating agents to overcome drug resistance and enhance therapeutic efficacy.